Business Cocktail Archives - DelveInsight

Business Cocktail

Entasis
Business Cocktail

Zymeworks Daiichi I-O deal could potentially be worth USD 485 million Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the ...


transthyretin amyloidosis
Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set...

Atara Biotherapeutics hires ex-Genentech SVP to lead its global R&D program Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&D global head. During the time in Gene...


Default Blog Image
Horizon Discovery declines Abcam’s USD 367 million takeover bid

Horizon Discovery declines Abcam’s USD 367 million takeover bid Horizon Discovery has recently rejected a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing...


BioGen
Business Cocktail

Novo Holdings optimistic about investments in life sciences Novo Holdings is planning to increase its investment in early & late stage biotechs. Its focus will be mainly in the U.S. and Europe...


BioGen
Business Cocktail

M&A activity of Sanofi and Bioverative for rare blood diseases Sanofi has strengthened its position in hematology & speciality medicine by acquiring Bioverativ, Biogen hemophilia & bloo...


BioGen
The Business Cocktail : Latest Pharma deals

Ionis pharmaceuticals recently licensed-out its antisense drug to AstraZeneca in deal total worth up to USD 330 million Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZe...


Default Blog Image
Adapsyn signed; Evolus filed; BioNTech signed a deal; Nordisk’s deal

Adapsyn signed a USD 162 million deal with Pfizer for microbe-mining project Adapsyn has recently signed a deal with Pfizer for the microbe-mining with the help of advance platform developed by the...


Entasis
December 7 Business Cocktail

AbbVie aims for best-in-class psoriasis prospect The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way. AbbVie...


Business Cocktail

Takeda and Portal Instruments partner to bring about needle-free form of drug delivery Takeda Pharmaceutical and Portal Instruments have partnered with a deal worth $100 million to develop a needle...


Default Blog Image
Business Cocktail

Chinese pharma company Shanghai Fosun to acquire 74% stake in Indian company Gland Pharma for $1.09 billion In July last year Chinese company Shanghai Fosun Pharmaceutical announced to acquire 74%...


Editor's Pick
Bone Metastasis Market: A Debilitating Consequence for Many Tumors

In advanced cancer patients, the most common site for the occurrence of metastasis is c...

Evaluating the Role of Digital Therapeutics as an Alternative to Conventional...

Depression is a mental condition characterized by prolonged series of poor moods, loss ...

Exploring the Market Potential of the Upcoming Therapies for the Myasthenia G...

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It ...

Scrutinizing the West Syndrome Market Space from Growth Perspectives

West syndrome is a rare form of neurological disorder, an age-related specific Epilepti...

Recent Inclination of Pharma Companies, Emerging Pipeline Therapies Drive the...

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. ...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.